Abstract:Depression, a pervasive and disabling mental health disorder, presents a global healthcare challenge. Despite persistent research on its etiology and pathophysiology, many aspects remain unclear. Predominant neurobiological research and traditional pharmacotherapies have pointed out the monoamine hypothesis as a pivotal factor in the pathophysiology of depression. However, emerging perspectives on the monoamine hypothesis highlight the significance of the cholinergic system, a major regulator of diverse CNS functions encompassing attention, arousal, cognition, and memory. Cognitive impairments were frequently observed in depression along with other symptoms i.e. low mood and anhedonia. A comprehensive literature search was conducted across multiple databases (PubMed, Scopus, and Web of Science) from their inception until May 2023. We screened 1,200 articles, of which 400 full-text articles were assessed for eligibility, and 231 studies met the inclusion criteria. The review included both pre-clinical and clinical studies focusing on the role of acetylcholine (ACh) and its receptors in depression. Data extraction and quality assessment were performed independently by two reviewers. In literature, both pre-clinical and clinical studies suggest that elevated central ACh levels may contribute to depression, prompting investigations into intervention strategies targeting mAChRs/nAChRs and AChE. These receptors have become a critical target in drug-design strategies aimed at addressing depression-like symptoms. In addition, research has demonstrated a significant antidepressant-like effect of AChEIs in a dose-dependent manner in animal models. Hence, this evidence over the past decades underscores the pivotal role of the cholinergic system in mood regulation, offering promise for novel depression treatments. In this review, we tried to summarize the historical evolution of the cholinergic system from early discoveries to its role in the pathophysiology of depression. It presents evidence for the involvement of mAChRs and nAChRs, as well as AChE, in depression. By outlining the cholinergic theory of depression, this review suggests a novel therapeutic approach, emphasizing the role of ACh in the complex depression pathophysiology, and presenting avenues for further research and the development of targeted interventions.

Does the application of acetylcholinesterase inhibitors in the treatment of Alzheimer’s disease lead to depression?

The State of The Art on Acetylcholinesterase Inhibitors in the Treatment of Alzheimer’s Disease

Anti-Inflammatory Properties of Acetylcholinesterase Inhibitors Administred in Alzheimers Disease

Acetylcholine and Depression: Scrutinizing Future Therapeutic Targets for Novel Drug Development

Acetylcholinesterase inhibitors for treating dementia symptoms - a safety evaluation

Efficacy of acetylcholinesterase inhibitors in Alzheimer's disease

Acetyl-cholinesterase-inhibitors reconsidered. A narrative review of post-marketing studies on Alzheimer's disease

Inhibitory Actions of Antidepressants, Hypnotics, and Anxiolytics on Recombinant Human Acetylcholinesterase Activity

Efficacy of Acetylcholinesterase Inhibitors on Cognitive Function in Alzheimer’s Disease. Review of Reviews

Specific Cholinesterase Inhibitors: A Potential Tool To Assist In Management Of Alzheimer Disease

Muscarinic and nicotinic acetylcholine receptor agonists: current scenario in Alzheimer's disease therapy

A New Therapeutic Target in Alzheimer's Disease Treatment: Attention to Butyrylcholinesterase

Selective Acetyl- And Butyrylcholinesterase Inhibitors Reduce Amyloid-Beta Ex Vivo Activation Of Peripheral Chemo-Cytokines From Alzheimer'S Disease Subjects: Exploring The Cholinergic Anti-Inflammatory Pathway

Research Progress of Acetylcholinesterase Inhibitors in the Treatment of Alzheimer＇s Disease

Naturally Occurring Acetylcholinesterase Inhibitors and Their Potential Use for Alzheimer's Disease Therapy

Dual-target inhibitors based on acetylcholinesterase: Novel agents for Alzheimer's disease

Safety of Cholinesterase Inhibitors and NMDA Receptors Antagonists for the Treatment of Patients with Dementia

Non-Alkaloid Cholinesterase Inhibitory Compounds from Natural Sources

Reimagining cholinergic therapy for Alzheimer's disease

Advances in Therapeutics to Alleviate Cognitive Decline and Neuropsychiatric Symptoms of Alzheimer's Disease

Acetylcholinesterase Inhibitors in the Treatment of Neurodegenerative Diseases and the Role of Acetylcholinesterase in their Pathogenesis